News headlines about TRACON Pharmaceuticals (NASDAQ:TCON) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.8459657164195 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of TRACON Pharmaceuticals (NASDAQ:TCON) traded down $0.27 on Thursday, hitting $2.48. 159,279 shares of the stock traded hands, compared to its average volume of 218,675. TRACON Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $4.60. The stock has a market capitalization of $49.70, a P/E ratio of -2.18 and a beta of 2.23. The company has a current ratio of 3.06, a quick ratio of 3.06 and a debt-to-equity ratio of 0.27.
TRACON Pharmaceuticals (NASDAQ:TCON) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.09. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 96.65%. sell-side analysts forecast that TRACON Pharmaceuticals will post -0.91 EPS for the current year.
Separately, Zacks Investment Research downgraded shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research note on Friday, January 5th.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/15/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-tracon-pharmaceuticals-tcon-share-price.html.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.